NewLink Genetics

NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.
Company Growth (employees)
Type
Public
HQ
Ames, US
Founded
1999
Size (employees)
122 (est)-41%
NewLink Genetics was founded in 1999 and is headquartered in Ames, US

NewLink Genetics Office Locations

NewLink Genetics has offices in Ames, Austin and Devens
Ames, US (HQ)
5100 2503 S Loop Dr
Devens, US
108 94 Jackson Rd
Austin, US
100 2700 Vía Fortuna

NewLink Genetics Data and Metrics

NewLink Genetics Financial Metrics

NewLink Genetics's revenue was reported to be $35.8 m in FY, 2016 which is a 48% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

35.8 m

Revenue growth (FY, 2015 - FY, 2016), %

(48%)

Net income (FY, 2016)

(85.2 m)

EBIT (FY, 2016)

(90.8 m)

Market capitalization (26-May-2017)

419.1 m

Closing share price (26-May-2017)

15.2

Cash (31-Dec-2016)

131.5 m
NewLink Genetics's current market capitalization is $419.1 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.1 m172.6 m68.5 m35.8 m

Revenue growth, %

15691%(60%)(48%)

Operating expense total

147.3 m55 m102.1 m126.5 m

EBIT

(138.8 m)117.6 m(33.6 m)(90.8 m)

EBIT margin, %

(12702%)68%(49%)(254%)

Interest expense

33 k26 k105 k22 k

Interest income

12 k86 k78 k237 k

Income tax expense

(130 k)(14.8 m)(6.7 m)5.4 m

Net Income

(136.5 m)102.9 m(40.4 m)(85.2 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

61.3 m190.4 m195.6 m131.5 m

Accounts Receivable

1.3 m3.7 m5.4 m24.5 m

Inventories

5 m5.9 m

Current Assets

64 m230.5 m208.1 m167.9 m

PP&E

6.8 m

Total Assets

70.6 m238.1 m218.5 m174.7 m

Accounts Payable

612 k2.4 m3.7 m22.9 m

Current Liabilities

3.9 m25 m14.8 m37.9 m

Non-Current Liabilities

8.4 m9.3 m7.9 m7.4 m

Total Liabilities

12.2 m34.3 m22.8 m45.3 m

Additional Paid-in Capital

194 m236.8 m276.6 m295.5 m

Retained Earnings

(33.1 m)(80.4 m)(165.5 m)

Total Equity

58.3 m203.8 m195.8 m129.5 m

Financial Leverage

1.2 x1.2 x1.1 x1.3 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(31.2 m)102.9 m(40.4 m)(85.2 m)

Depreciation and Amortization

891 k1.1 m1.6 m2.1 m

Accounts Receivable

1.1 m(2.4 m)(1.7 m)(19 m)

Inventories

3.4 m

Accounts Payable

(359 k)7.9 m245 k24.8 m

Cash From Operating Activities

61.3 m109.1 m(24.1 m)(65.9 m)

Purchases of PP&E

(1.4 m)(1.7 m)(4 m)(2.2 m)

Cash From Investing Activities

(141 k)(13.8 m)6.2 m(66 k)

Short-term Borrowings

(154 k)(158 k)

Cash From Financing Activities

67 m33.9 m23.1 m1.9 m

Interest Paid

34 k26 k105 k22 k

Income Taxes Paid

26.4 m4.8 m1 m
Y, 2016

Financial Leverage

1.3 x

NewLink Genetics Market Value History

NewLink Genetics Company Life and Culture

You may also be interested in